For more information about any of our clinical studies or study site locations, go to the U.S. FDA Clinical Trials Registry ,contact us directly at firstname.lastname@example.org or visit Idera’s Clinical Trials Website.
Current open trials
A Phase 1/2 clinical trial of intratumoral IMO-2125 in combination with ipilimumab (a CTLA-4 antibody) in patients with metastatic melanoma is underway at MD Anderson Cancer Center in Texas. The trial is expected to enroll approximately 45 patients with the goal of determining the maximum tolerated dose, as well as the efficacy of IMO-2125 when administered intratumorally in combination with either ipilimumab or pembrolizumab. For more information on this study, go to the U.S. FDA Clinical Trial Registry Website ,contact Idera at email@example.com or visit Idera’s Clinical Trials Website.
A randomized, double-blind, placebo-controlled Phase 2 clinical trial of IMO-8400 in adult patients with dermatomyositis is currently enrolling patients with active skin disease and muscle weakness who are unable to control their symptoms with current therapies. The trial will assess the compound’s safety, tolerability, and clinical activity when given to patients via weekly dosing for up to 24 weeks. Eligibility criteria include a confirmed diagnosis of dermatomyositis, evidence of active skin and muscle disease, and a stable treatment regimen meeting pre-specified criteria prior to enrollment.